Survival trends in young patients with Waldenstrom macroglobulinemia (WM).

被引：0
|
作者：
Vallumsetla, Nishanth
Paludo, Jonas
Gertz, Morie
Ansell, Stephen Maxted
Go, Ronald S.
Rajkumar, Vincent
Kyle, Robert A.
Buadi, Francis
Dispenzieri, Angela
Lacy, Martha
Dingli, David
Hayman, Suzanne R.
Leung, Nelson
Kumar, Shaji
Kapoor, Prashant
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8596
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Waldenstrom's macroglobulinemia (WM) in Japan. Results of a retrospective survey
    Toumilhac, O.
    Kumagawa, N.
    Ishitsuka, K.
    Morel, P.
    Tamura, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 224 - 224
  • [32] Mutations the April/Taci/Traf pathway in Waldenstrom's macroglobulinemia (WM)
    Hunter, Z. R.
    Leleu, X.
    Adamia, S.
    Hatjiharissi, E.
    Xu, L.
    Ioakimidis, L.
    Moreau, A. S.
    Moreau, A. S.
    O'Connor, K. E.
    Soumerai, J.
    Patterson, C.
    Hamilton, S.
    Verselis, S.
    Fox, E. A.
    Treon, S. P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 220 - 220
  • [33] IDELALISIB MONOTHERAPY RESULTS IN DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA (WM)
    Coutre, S.
    Leonard, J.
    Flowers, C.
    Davies, A.
    Jurczak, W.
    Byrd, J.
    Spurgeon, S.
    Peterman, S.
    Holes, L.
    Cho, Y.
    Sorenson, B.
    Godfrey, W.
    Gopal, A.
    HAEMATOLOGICA, 2015, 100 : 273 - 273
  • [34] Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstrom's macroglobulinemia (WM): Results in 25 patients
    Vargaftig, J.
    Pegourie-Bandelier, B.
    Mahe, B.
    Le Gouill, S.
    Brottier-Mancini, E.
    Delarue, R.
    Buzyn, A.
    Maigre, M.
    Gardin, C.
    Choquet, S.
    Leblond, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 227 - 227
  • [35] Modified Staging System for Waldenstrom Macroglobulinemia (MSS-WM): A MultiInstitutional Externally Validated Prognostic Model for Active/Symptomatic Waldenstrom Macroglobulinemia
    Zanwar, Saurabh
    Le-Rademacher, Jennifer
    Durot, Eric
    D'Sa, Shirley
    Abeykoon, Jithma Prasad
    Mondello, Patrizia
    Kumar, Shaji Kunnathu
    Sarosiek, Shayna R.
    Paludo, Jonas
    Chhabra, Saurabh
    Cook, Joselle
    Parrondo, Ricardo
    Dispenzieri, Angela
    Gonsalves, Wilson I.
    Muchtar, Eli
    Ailawadhi, Sikander
    Kyle, Robert
    Rajkumar, Vincent
    Delmer, Alain Jacques
    Fonseca, Rafael
    Gertz, Morie A.
    Treon, Steven P.
    Ansell, Stephen M.
    Castillo, Jorge J.
    Kapoor, Prshant
    BLOOD, 2023, 142
  • [36] ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrom macroglobulinemia (WM).
    Tam, Constantine Si Lun
    Opat, Stephen
    D'Sa, Shirley
    Jurczak, Wojciech
    Lee, Hui-Peng
    Cull, Gavin
    Owen, Roger G.
    Marlton, Paula
    Wahlin, Bjorn E.
    Tedeschi, Alessandra
    Castillo, Jorge J.
    Siddiqi, Tanya
    Buske, Christian
    Leblond, Veronique
    Chan, Wai Y.
    Schneider, Jingjing
    Ro, Sunhee K.
    Cohen, Aileen
    Huang, Jane
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] ASPEN: Results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrom Macroglobulinemia (WM)
    Buske, C.
    Dimopoulos, M.
    Opat, S.
    D'Sa, S.
    Jurczak, W.
    Lee, H-P
    Cull, G.
    Owen, R. G.
    Marlton, P.
    Wahlin, B. E.
    Garcia, Sanz R.
    McCarthy, H.
    Mulligan, S.
    Tedeschi, A.
    Castillo, J.
    Czyz, J.
    Fernandez De Larrea, C.
    Belada, D.
    Libby, E.
    Matous, J.
    Motta, M.
    Siddiqi, T.
    Tani, M.
    Trneny, M.
    Minnema, M.
    Leblond, V
    Chan, W. Y.
    Schneider, J.
    Cohen, A.
    Huang, J.
    Tam, C. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 107 - 108
  • [38] COMPARISON OF HEALTHCARE RESOURCE UTILIZATION AND COSTS FOR WALDENSTROM'S MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB OR CHEMOIMMUNOTHERAPY
    Iyengar, R.
    Malangone-Monaco, E.
    Sugg, C.
    Arango-Hisijara, I
    Chen, Z.
    DeYoung, K.
    Chan, C.
    Giafis, N.
    VALUE IN HEALTH, 2019, 22 : S76 - S76
  • [39] ASPEN: RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB FOR PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA (WM)
    Tedeschi, A.
    Dimopoulos, M.
    Opat, S.
    D'Sa, S.
    Jurczak, W.
    Lee, H.
    Cull, G.
    Owen, R.
    Marlton, P.
    Wahlin, B.
    Garcia Sanz, R.
    McCarthy, H.
    Mulligan, S.
    Castillo, J.
    Czyz, J.
    Fernandez De Larrea, C.
    Belada, D.
    Libby, E.
    Matous, J.
    Motta, M.
    Siddiqi, T.
    Tani, M.
    Trneny, M.
    Minnema, M.
    Buske, C.
    Leblond, V.
    Chan, W.
    Schneider, J.
    Cohen, A.
    Huang, J.
    Tam, C.
    HAEMATOLOGICA, 2021, 106 (10) : 9 - 10
  • [40] Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstrom's macroglobulinemia (WM):: Results in 21 patients (pts).
    Vargaftig, Jacques
    Pegourie-Bandelier, Brigitte
    Mahe, Beatrice
    Le Gouill, Steven
    Brottier-Mancini, Elisabeth
    Delarue, Richard
    Buzyn, Agnes
    Raphael, Martine
    Choquet, Sylvain
    Leblond, Veronique
    BLOOD, 2006, 108 (11) : 264B - 264B
12345